Overall Survival With Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Study Update
Panelists discuss how the CARTITUDE-4 study data highlights the significant survival benefits of ciltacabtagene autoleucel compared to with standard of care in patients with lenalidomide-refractory multiple myeloma, emphasizing its potential to reshape treatment paradigms in this challenging population.
EP. 1: Impact of CAR T-Cell Therapy in R/R MM
October 11th 2024Panelists discuss how chimeric antigen receptor (CAR) -T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (R/R MM), demonstrating remarkable efficacy and offering new hope for patients with limited therapeutic options.
EP. 2: Overview of CARTITUDE-4: Study Design, Baseline Characteristics, and Efficacy
October 18th 2024Panelists discuss how the CARTITUDE-4 study data provide a comprehensive overview of its design, baseline characteristics, and efficacy outcomes, highlighting the potential of ciltacabtagene autoleucel in improving treatment results for patients with lenalidomide-refractory multiple myeloma.
EP. 3: Long-Term CARTITUDE-4 Study Update in MM
October 25th 2024Panelists discuss how data from the long-term CARTITUDE-4 study update in multiple myeloma (MM) highlight the sustained efficacy and safety of ciltacabtagene autoleucel, reinforcing its role as a promising treatment option for patients with lenalidomide-refractory disease.
EP. 4: Long-Term CARTITUDE-4 Update: ORR and DOR
November 1st 2024Panelists discuss how data from the long-term update from CARTITUDE-4 reveal impressive overall response rates (ORRs) and duration of response (DOR) for ciltacabtagene autoleucel, reinforcing its effectiveness in treating lenalidomide-refractory multiple myeloma.
EP. 5: Long-Term CARTITUDE 4: Rate of MRD Negativity
November 8th 2024Panelists discuss how data from the long-term CARTITUDE-4 update reveal a notable rate of minimal residual disease (MRD) negativity with ciltacabtagene autoleucel, emphasizing its potential to enhance long-term outcomes in patients with lenalidomide-refractory multiple myeloma.
EP. 6: Safety Data from the Long-Term CARTITUDE-4 Update
November 15th 2024Panelists discuss how the safety data from the long-term CARTITUDE-4 update demonstrate a manageable adverse event profile for ciltacabtagene autoleucel, supporting its continued use in patients with lenalidomide-refractory multiple myeloma.
